Estimating Global Patient Needs and Market Potential for Priority Health Technologies Addressing Antimicrobial Resistance
The Board of Members (BoM) of the Global Antimicrobial Resistance Research and Development Hub (Global AMR R&D Hub) sought to further understand the market attractiveness of new AMR-related health technologies that meet the highest priority unmet needs. The BoM initiated a quantitative study under the supervision of a global Expert Advisory Group (EAG), with broad geographic and technical representation across the One Health spectrum. They in turn commissioned the support of a specialist external contractor (groupH) to quantify the patient needs and market potentials in the areas they identified.
The EAG adopted a human patient-need led approach for its initial priorities, resulting in the identification of four priority health technologies – two small-molecule therapeutics and two point-of-care (POC) diagnostics – that were investigated in more detail by building epidemiological and commercial models, in order to provide an assessment of the patient need and market attractiveness.
The study outcomes reported here will be used to inform policy-makers of the scale of this part of the AMR challenge and to support current thinking on market intervention.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.